NYSE$HAE

Haemonetics Corp. · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

Haemonetics' Q4 2022 financial results were reported, showing revenue increase and strong performance in Hospital business unit.

Haemonetics reported a strong fourth quarter, with revenue up 17.8% to $265 million. The company saw growth across its business units, particularly in Hospital, and managed to mitigate inflationary pressures through its Operational Excellence Program. Adjusted earnings per diluted share increased by 41.3% to $0.65.

  • Revenue increased by 17.8% to $265 million.
  • Organic revenue increased by 18.9%.
  • Adjusted earnings per diluted share increased by 41.3% to $0.65.
  • Operating income was $19.2 million, compared to an operating loss of $21.2 million in the same period last year.

Headline financials

Total Revenue

$265M

Previous: $225M+17.8%
EPS (adj)

$0.65

Previous: $0.46+41.3%
Capital Expenditures

$35.1M

Previous: $11.6M+201.9%
Free Cash Flow

$42M

Previous: -$10.1M+516.5%
Net Income

$9.74M

Previous: -$11M+188.2%
Operating Income

$19.2M

Previous: -$21.2M+190.7%
Gross Profit

$136M

Previous: $81.8M+66.6%
Cash & Equivalents

$259M

Previous: $192M+34.9%
Total Assets

$1.86B

Previous: $1.82B+2.2%
Stock-Based Comp

$5.1M

Previous: $7.11M-28.3%

Revenue & EPS history

Haemonetics · Revenue · Quarterly

$265M

Q4 2022+17.8%vs Q4 2021
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Haemonetics · $260M total across 3 segments · Q4 2022

  • Plasma
    $101M+20.8%
  • Hospital
    $85.7M+37.9%
  • Blood Center
    $73.1M-0.9%

Forward guidance

The Company issued its fiscal 2023 GAAP total revenue growth guidance of 5 – 9% and organic revenue growth guidance as follows:Organic1Total revenue6 - 10%Plasma revenue7 - 12%Hospital Revenue16 - 19%Blood Center revenue(4 - 7%)

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

+1.4%

Avg return

Earnings day

+4.1%

Avg return

5 days after

+6.5%

Avg return

30 days after

56%

38 / 68 earnings

Positive

+31.8%

Q2 2026

Best reaction

-15.0%

Q4 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+3.3%+2.5%+35.5%
Q3 2026-1.4%-9.8%-2.8%
Q2 2026+31.8%+41.4%+65.5%
Q4 2025+5.9%+7.6%+9.7%
Q3 2025-11.6%-13.6%-3.6%
Q2 2025+11.8%+19.5%+3.9%
Q1 2025-10.1%-13.4%-14.6%
Q4 2024+2.8%+4.4%-8.2%
Q3 2024-3.8%-7.0%+3.2%
Q2 2024+2.4%+2.5%-2.5%
Q1 2024+2.0%+3.0%-0.8%
Q4 2023+7.6%+7.4%+6.1%
Q3 2023-5.4%-8.2%-12.2%
Q2 2023+4.1%-1.7%+3.5%
Q1 2023+8.1%+12.3%+13.7%
Q4 2022+3.9%+14.1%+31.5%
Q3 2022+21.2%+24.5%+18.9%
Q2 2022-13.5%-15.7%-24.8%
Q1 2022+8.4%+1.8%+16.8%
Q4 2021-6.4%-5.4%+0.4%
Q3 2021+12.8%+21.1%+4.0%
Q2 2021-3.7%+5.6%+13.2%
Q1 2021-12.7%-8.5%+3.3%
Q4 2020-8.8%-3.4%-11.1%
Q3 2020+7.2%+7.7%-7.3%
Q2 2020+0.3%+0.5%-0.1%
Q1 2020+10.5%+13.5%+10.8%
Q4 2019+2.8%+3.4%+10.0%
Q3 2019-12.2%-14.3%-13.0%
Q2 2019+9.1%+5.8%-0.2%
Q1 2019+4.8%+2.7%+14.4%
Q4 2018+5.8%+11.2%+18.9%
Q3 2018+14.8%+13.1%+20.5%
Q2 2018+15.8%+16.4%+20.8%
Q1 2018+4.2%+3.2%+3.9%
Q4 2017-1.9%-4.4%-4.0%
Q3 2017-10.1%-9.0%-7.3%
Q2 2017+10.5%+13.8%+16.5%
Q1 2017+13.8%+16.8%+22.6%
Q4 2016-15.0%
Q3 2016+5.9%
Q2 2016-3.9%
Q1 2016+1.5%
Q4 2015-3.9%
Q3 2015+7.0%
Q2 2015-5.9%
Q1 2015-1.4%
Q4 2014-8.0%
Q3 2014-2.6%
Q2 2014+1.5%
Q1 2014+0.7%
Q4 2013-1.4%
Q3 2013-5.6%
Q2 2013+4.3%
Q1 2013-0.1%
Q4 2012+4.2%
Q3 2012-1.0%
Q2 2012+0.4%
Q1 2012+3.1%
Q4 2011+1.3%
Q4 2009+1.3%
Q3 2010-1.3%
Q3 2011-1.3%
Q2 2011+1.7%
Q1 2010-2.5%
Q2 2010-2.5%
Q1 2011-2.5%
Q4 2010-2.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro